Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT201 Injection) as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors

NCT06144671 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.

NCT NCT06144671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06144671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT201 Injection) as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
Lead sponsor
Grit Biotechnology
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 1, 2025
Completion date
December 30, 2027
Enrollment
78 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors